AAPL349.18+5.35 (+1.56%) ▲|ABBV288.90+2.91 (+1.02%) ▲|ABT104.40+1.76 (+1.71%) ▲|ACN242.99-0.41 (-0.17%) ▼|ADBE246.45-3.31 (-1.33%) ▼|AMAT424.03+8.03 (+1.93%) ▲|AMD569.90-8.54 (-1.48%) ▼|AMGN458.24+6.41 (+1.42%) ▲|AMT184.31+0.56 (+0.30%) ▲|AMZN246.11-8.50 (-3.34%) ▼|AVGO344.50-7.31 (-2.08%) ▼|AXP324.21+6.27 (+1.97%) ▲|BA173.94+6.80 (+4.07%) ▲|BAC51.73+0.88 (+1.73%) ▲|BKNG150.18+2.24 (+1.51%) ▲|BLK1,171.22+13.34 (+1.15%) ▲|BMY60.68+0.11 (+0.17%) ▲|BNY149.96+1.37 (+0.92%) ▲|BRK-B543.61+3.27 (+0.61%) ▲|C126.42+2.31 (+1.86%) ▲|CAT656.78-56.60 (-7.93%) ▼|CL92.35+0.66 (+0.72%) ▲|CMCSA21.98+0.41 (+1.90%) ▲|COF208.78+3.90 (+1.90%) ▲|COP149.24+0.18 (+0.12%) ▲|COST989.27+6.54 (+0.67%) ▲|CRM231.59-10.52 (-4.35%) ▼|CSCO109.12-1.17 (-1.06%) ▼|CVS90.59+0.64 (+0.71%) ▲|CVX230.10+0.90 (+0.39%) ▲|DE659.11+18.44 (+2.88%) ▲|DHR236.92+2.85 (+1.22%) ▲|DIS110.76+1.72 (+1.57%) ▲|DUK125.60+2.03 (+1.64%) ▲|EMR170.71+3.00 (+1.79%) ▲|FDX308.94+4.36 (+1.43%) ▲|GD369.13+14.78 (+4.17%) ▲|GE312.18+11.05 (+3.67%) ▲|GEV904.82+26.79 (+3.05%) ▲|GILD161.15+1.95 (+1.22%) ▲|GM85.76+3.28 (+3.98%) ▲|GOOG283.17-38.72 (-12.03%) ▼|GOOGL285.10-39.80 (-12.25%) ▼|GS934.68+9.51 (+1.03%) ▲|HD325.65+8.09 (+2.55%) ▲|HON221.15+1.89 (+0.86%) ▲|IBM254.77+1.55 (+0.61%) ▲|INTC92.46-3.07 (-3.21%) ▼|INTU330.00+1.81 (+0.55%) ▲|ISRG447.80+3.62 (+0.82%) ▲|JNJ274.90+3.86 (+1.42%) ▲|JPM344.08+4.78 (+1.41%) ▲|KO92.30+0.57 (+0.62%) ▲|LIN499.84-8.32 (-1.64%) ▼|LLY1,371.02+82.72 (+6.42%) ▲|LMT646.44+16.69 (+2.65%) ▲|LOW204.43+6.03 (+3.04%) ▲|LRCX257.50+3.68 (+1.45%) ▲|MA635.83+25.52 (+4.18%) ▲|MCD255.36+4.86 (+1.94%) ▲|MDLZ62.09+0.22 (+0.36%) ▲|MDT96.78+2.00 (+2.11%) ▲|META629.89+17.40 (+2.84%) ▲|MMM176.37+3.57 (+2.07%) ▲|MO75.57+2.58 (+3.53%) ▲|MRK147.55+6.62 (+4.70%) ▲|MS192.58+2.45 (+1.29%) ▲|MSFT524.03-6.99 (-1.32%) ▼|MU945.99-37.24 (-3.79%) ▼|NEE82.20+1.18 (+1.46%) ▲|NFLX62.09+0.10 (+0.15%) ▲|NKE38.39+1.24 (+3.32%) ▲|NOW112.01-38.12 (-25.39%) ▼|NVDA213.52-1.87 (-0.87%) ▼|ORCL139.64-4.91 (-3.39%) ▼|PEP132.93+0.30 (+0.23%) ▲|PFE29.73+0.28 (+0.94%) ▲|PG159.01+0.75 (+0.47%) ▲|PLTR194.55-2.27 (-1.15%) ▼|PM205.74+3.10 (+1.53%) ▲|QCOM183.24+0.27 (+0.15%) ▲|RTX200.65+4.81 (+2.45%) ▲|SBUX104.56+1.36 (+1.32%) ▲|SCHW89.72+0.96 (+1.08%) ▲|SO93.07+1.55 (+1.69%) ▲|SPG214.71+3.47 (+1.64%) ▲|T21.03+0.33 (+1.59%) ▲|TMO709.33+5.18 (+0.74%) ▲|TMUS148.77+0.69 (+0.47%) ▲|TSLA405.89+1.67 (+0.41%) ▲|TXN309.48-0.35 (-0.11%) ▼|UBER65.29+0.02 (+0.02%) ▲|UNH405.79-1.31 (-0.32%) ▼|UNP299.08+1.28 (+0.43%) ▲|UPS106.50+0.88 (+0.83%) ▲|USB60.65+1.05 (+1.76%) ▲|V409.94+9.34 (+2.33%) ▲|VZ43.70+0.52 (+1.19%) ▲|WFC85.09+1.42 (+1.69%) ▲|WMT121.05+2.28 (+1.92%) ▲|XOM182.01-0.01 (-0.01%) ▼|AAPL349.18+5.35 (+1.56%) ▲|ABBV288.90+2.91 (+1.02%) ▲|ABT104.40+1.76 (+1.71%) ▲|ACN242.99-0.41 (-0.17%) ▼|ADBE246.45-3.31 (-1.33%) ▼|AMAT424.03+8.03 (+1.93%) ▲|AMD569.90-8.54 (-1.48%) ▼|AMGN458.24+6.41 (+1.42%) ▲|AMT184.31+0.56 (+0.30%) ▲|AMZN246.11-8.50 (-3.34%) ▼|AVGO344.50-7.31 (-2.08%) ▼|AXP324.21+6.27 (+1.97%) ▲|BA173.94+6.80 (+4.07%) ▲|BAC51.73+0.88 (+1.73%) ▲|BKNG150.18+2.24 (+1.51%) ▲|BLK1,171.22+13.34 (+1.15%) ▲|BMY60.68+0.11 (+0.17%) ▲|BNY149.96+1.37 (+0.92%) ▲|BRK-B543.61+3.27 (+0.61%) ▲|C126.42+2.31 (+1.86%) ▲|CAT656.78-56.60 (-7.93%) ▼|CL92.35+0.66 (+0.72%) ▲|CMCSA21.98+0.41 (+1.90%) ▲|COF208.78+3.90 (+1.90%) ▲|COP149.24+0.18 (+0.12%) ▲|COST989.27+6.54 (+0.67%) ▲|CRM231.59-10.52 (-4.35%) ▼|CSCO109.12-1.17 (-1.06%) ▼|CVS90.59+0.64 (+0.71%) ▲|CVX230.10+0.90 (+0.39%) ▲|DE659.11+18.44 (+2.88%) ▲|DHR236.92+2.85 (+1.22%) ▲|DIS110.76+1.72 (+1.57%) ▲|DUK125.60+2.03 (+1.64%) ▲|EMR170.71+3.00 (+1.79%) ▲|FDX308.94+4.36 (+1.43%) ▲|GD369.13+14.78 (+4.17%) ▲|GE312.18+11.05 (+3.67%) ▲|GEV904.82+26.79 (+3.05%) ▲|GILD161.15+1.95 (+1.22%) ▲|GM85.76+3.28 (+3.98%) ▲|GOOG283.17-38.72 (-12.03%) ▼|GOOGL285.10-39.80 (-12.25%) ▼|GS934.68+9.51 (+1.03%) ▲|HD325.65+8.09 (+2.55%) ▲|HON221.15+1.89 (+0.86%) ▲|IBM254.77+1.55 (+0.61%) ▲|INTC92.46-3.07 (-3.21%) ▼|INTU330.00+1.81 (+0.55%) ▲|ISRG447.80+3.62 (+0.82%) ▲|JNJ274.90+3.86 (+1.42%) ▲|JPM344.08+4.78 (+1.41%) ▲|KO92.30+0.57 (+0.62%) ▲|LIN499.84-8.32 (-1.64%) ▼|LLY1,371.02+82.72 (+6.42%) ▲|LMT646.44+16.69 (+2.65%) ▲|LOW204.43+6.03 (+3.04%) ▲|LRCX257.50+3.68 (+1.45%) ▲|MA635.83+25.52 (+4.18%) ▲|MCD255.36+4.86 (+1.94%) ▲|MDLZ62.09+0.22 (+0.36%) ▲|MDT96.78+2.00 (+2.11%) ▲|META629.89+17.40 (+2.84%) ▲|MMM176.37+3.57 (+2.07%) ▲|MO75.57+2.58 (+3.53%) ▲|MRK147.55+6.62 (+4.70%) ▲|MS192.58+2.45 (+1.29%) ▲|MSFT524.03-6.99 (-1.32%) ▼|MU945.99-37.24 (-3.79%) ▼|NEE82.20+1.18 (+1.46%) ▲|NFLX62.09+0.10 (+0.15%) ▲|NKE38.39+1.24 (+3.32%) ▲|NOW112.01-38.12 (-25.39%) ▼|NVDA213.52-1.87 (-0.87%) ▼|ORCL139.64-4.91 (-3.39%) ▼|PEP132.93+0.30 (+0.23%) ▲|PFE29.73+0.28 (+0.94%) ▲|PG159.01+0.75 (+0.47%) ▲|PLTR194.55-2.27 (-1.15%) ▼|PM205.74+3.10 (+1.53%) ▲|QCOM183.24+0.27 (+0.15%) ▲|RTX200.65+4.81 (+2.45%) ▲|SBUX104.56+1.36 (+1.32%) ▲|SCHW89.72+0.96 (+1.08%) ▲|SO93.07+1.55 (+1.69%) ▲|SPG214.71+3.47 (+1.64%) ▲|T21.03+0.33 (+1.59%) ▲|TMO709.33+5.18 (+0.74%) ▲|TMUS148.77+0.69 (+0.47%) ▲|TSLA405.89+1.67 (+0.41%) ▲|TXN309.48-0.35 (-0.11%) ▼|UBER65.29+0.02 (+0.02%) ▲|UNH405.79-1.31 (-0.32%) ▼|UNP299.08+1.28 (+0.43%) ▲|UPS106.50+0.88 (+0.83%) ▲|USB60.65+1.05 (+1.76%) ▲|V409.94+9.34 (+2.33%) ▲|VZ43.70+0.52 (+1.19%) ▲|WFC85.09+1.42 (+1.69%) ▲|WMT121.05+2.28 (+1.92%) ▲|XOM182.01-0.01 (-0.01%) ▼|
17.5 C
New York
Thursday, October 29, 2026

Tag: pharmaceutical

newsFORsourcecompanycontentinformationreleases1market

Dizal’s ZEGFROVY® (sunvozertinib) Receives FDA Accelerated Approval as the Only Targeted Oral Treatment for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

ZEGFROVY is the only approved targeted oral treatment for NSCLC with EGFR exon20insApproval follows the U.S. FDA's Priority Review and is supported by the pivotal WU-KONG1 Part B study, in which...

Sleep Apnea Market to Accelerate Substantially at a CAGR of 20% During the Study Period (2020-2034) | DelveInsight

The sleep apnea market growth is driven by rising awareness, technological advancements, and demand for personalized care. Companies innovate therapies and solutions for better...

WST DEADLINE: ROSEN, A LONGSTANDING FIRM, Encourages West Pharmaceutical Services, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important July...

NEW YORK, July 02, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of West Pharmaceutical Services, Inc. (NYSE: WST) between February 16, 2023 and February 12, 2025, both dates inclusive (the “Class Period”), of the important July 7, 2025 lead plaintiff deadline.

Mesa Laboratories, Inc. to Announce First Quarter Results on August 5, 2025

LAKEWOOD, Colo., July 02, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) will issue a press release with financial results for the first quarter of fiscal year 2026 at approximately 8:00 A.M. Eastern time on Tuesday, August 5, 2025.

Apotex receives Health Canada approval for Aflivu™, a biosimilar to Eylea®, available in pre-filled syringe and vial formats

TORONTO, July 2, 2025 /PRNewswire/ - Apotex Inc. ("Apotex" or the "Company"), the Canadian-based global health company, today announced that Health Canada has approved Aflivu™ (aflibercept),...

2 Day Pharmaceutical, Biopharmaceutical, Biologics and Medical Device FDA Inspection Preparedness and Compliance Seminar (ONLINE EVENT: September 3-4, 2025)

Join our two-day seminar designed for pharmaceutical, biopharmaceutical, biologics, and medical device professionals to master FDA inspections. Gain hands-on strategies to efficiently prepare, conduct, and respond. Includes slides, certificates, Q&A, and inspection handouts. Optimize outcomes. 
Join our two-day seminar designed for pharmaceutical, biopharmaceutical, biologics, and medical device professionals to master FDA inspections. Gain hands-on strategies to efficiently prepare, conduct, and respond. Includes slides, certificates, Q&A, and inspection handouts. Optimize outcomes.

Everest Medicines Announces Updated Positive Results in Preliminary Analysis of Phase 1b/2a Clinical Trial of EVER001, a Novel BTK Inhibitor for the Treatment of...

As of March 21st, 2025, longer follow-up data was collected from the ongoing Ph1b/2a study of EVER001: in Cohort 1, 11 patients completed 52...

Ebenbuild Secures Euro 2.3 Million EIC Grant to Scale Digital Twin Platform for Respiratory Health

Munich, Germany – July 2, 2025 -- Ebenbuild, a company developing personalized, AI-enabled digital twins of lungs to support clinical decisions and digital clinical trials, today announced that it has received Euro 2.3 million funding under the European Innovation Council (EIC) Accelerator program to advance its digital twin platform technology. In addition, the EIC fund will invest up to €10 million in future equity financing rounds raised by Ebenbuild. The funding will support the market launch of Twinhale, the first in silico trial software built for pulmonary drug delivery. The investment also underpins Ebenbuild’s broader platform strategy to transform respiratory care through personalized lung simulation – from drug development to mechanical ventilation optimization in critical care.

BioVersys and Shionogi Enter Into Global Research Collaboration For Broad-Spectrum Non-Tuberculous Mycobacteria (NTM) Clinical Candidate

Ad hoc announcement pursuant to Art. 53 LR

Johnson Controls Celebrates 140 years of Innovation and Leadership

Over 40 Years of Dedicated Partnership and Growth in Singapore's Transformation Journey SINGAPORE, July 2, 2025 /PRNewswire/ -- Johnson Controls (NYSE: JCI), the global leader for smart,...

NADPH Oxidase (NOX)-Replacement Therapies Market to Observe Stunning Growth During the Forecast Period (2025-2034) Across 7MM | DelveInsight

The NOX-targeted therapy market is expected to expand significantly over the upcoming years as more therapies move into late-stage development and gain regulatory approval....

NADPH Oxidase (NOX)-Replacement Therapies Market to Observe Stunning Growth During the Forecast Period (2025-2034) Across 7MM | DelveInsight

The NOX-targeted therapy market is expected to expand significantly over the upcoming years as more therapies move into late-stage development and gain regulatory approval....

GlucoTru Pro Releases 2025 Health Integrity Update on Blood Pressure & Blood Sugar Balance Innovation

In this 2025 public health alignment update, GlucoTru Pro emphasizes the growing consumer awareness of natural metabolic support strategies, including non-synthetic approaches to managing blood pressure, blood sugar, and overall wellness. This release provides new insights into public commentary themes, recent transparency in ingredient sourcing, and the alignment of the GlucoTru Pro formula with broader non-pharmaceutical health discussions. 
In this 2025 public health alignment update, GlucoTru Pro emphasizes the growing consumer awareness of natural metabolic support strategies, including non-synthetic approaches to managing blood pressure, blood sugar, and overall wellness. This release provides new insights into public commentary themes, recent transparency in ingredient sourcing, and the alignment of the GlucoTru Pro formula with broader non-pharmaceutical health discussions.

Dogecoin Cash Inc. (OTCQB: DOGP) Forms Dogecoin Treasury, Inc. to Support Development of Dogecoin-Related Tools and Infrastructure

Support Development of Dogecoin-Related Tools and Infrastructure 
Support Development of Dogecoin-Related Tools and Infrastructure

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPharmaceutical

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers